Literature DB >> 11369574

Bone status in cystic fibrosis.

M Sood1, G Hambleton, M Super, W D Fraser, J E Adams, M Z Mughal.   

Abstract

AIM: To investigate bone mineral status of children with cystic fibrosis (CF).
METHODS: In 29 children with CF and 49 matched controls, bone mineral content (BMC), projected bone area (BA), and areal bone mineral density (BMD) of the whole body, total hip, and lumbar spine (L1-L4) were measured using dual energy x ray absorptiometry. The BMC values at each site were adjusted for BA, height, and weight. At the lumbar spine, the bone mineral apparent density (BMAD) was calculated by dividing the BMC by the estimated volume, derived from BA. Vertebral (T12-L3) trabecular bone mineral density (vTBMD) was measured using quantitative computed tomography in children with CF. Calcaneal broadband ultrasound attenuation (BUA) was measured in CF patients and controls using quantitative ultrasound. The disease severity of CF children was evaluated by the Shwachman-Kulczycki (SK) score.
RESULTS: The mean BUA, whole body and regional BA, adjusted BMC, and areal BMD of children with CF were not different from those of controls. The mean BMAD of the lumbar spine was reduced in CF patients compared with controls, whereas the mean vTBMD standard deviation scores were significantly higher in CF patients. The median SK score of the CF group was 81 (range 42-100), indicating that as a group our CF patient population had relatively mild disease.
CONCLUSION: The normal vertebral BMC, decreased BMAD, and higher vTBMD suggests that the vertebral cortical thickness or density might be reduced in CF subjects. The overall bone mineral status of CF children with relatively mild disease was not different from size matched controls.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369574      PMCID: PMC1718803          DOI: 10.1136/adc.84.6.516

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  31 in total

1.  Long-term study of one hundred five patients with cystic fibrosis; studies made over a five- to fourteen-year period.

Authors:  H SHWACHMAN; L L KULCZYCKI
Journal:  AMA J Dis Child       Date:  1958-07

2.  New approaches for interpreting projected bone densitometry data.

Authors:  D R Carter; M L Bouxsein; R Marcus
Journal:  J Bone Miner Res       Date:  1992-02       Impact factor: 6.741

Review 3.  Noninvasive measurements of bone mass, structure, and strength: current methods and experimental techniques.

Authors:  K G Faulkner; C C Glüer; S Majumdar; P Lang; K Engelke; H K Genant
Journal:  AJR Am J Roentgenol       Date:  1991-12       Impact factor: 3.959

4.  Role of physical activity in the development of skeletal mass in children.

Authors:  C W Slemenda; J Z Miller; S L Hui; T K Reister; C C Johnston
Journal:  J Bone Miner Res       Date:  1991-11       Impact factor: 6.741

5.  Reduced serum 25-hydroxyvitamin D concentration and disordered mineral metabolism in patients with cystic fibrosis.

Authors:  T J Hahn; A E Squires; L R Halstead; D B Strominger
Journal:  J Pediatr       Date:  1979-01       Impact factor: 4.406

6.  Changes in vertebral bone density in black girls and white girls during childhood and puberty.

Authors:  V Gilsanz; T F Roe; S Mora; G Costin; W G Goodman
Journal:  N Engl J Med       Date:  1991-12-05       Impact factor: 91.245

7.  The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years.

Authors:  P Gärdsell; O Johnell; B E Nilsson
Journal:  Calcif Tissue Int       Date:  1991-08       Impact factor: 4.333

8.  Some biochemical indices of nutrition in treated cystic fibrosis patients.

Authors:  N W Solomons; J B Wagonfeld; C Rieger; R A Jacob; M Bolt; J V Horst; R Rothberg; H Sandstead
Journal:  Am J Clin Nutr       Date:  1981-04       Impact factor: 7.045

9.  Cystic fibrosis in the United Kingdom, 1968-1988: incidence, population and survival.

Authors:  J A Dodge; S Morison; P A Lewis; E C Colest; D Geddes; G Russell; A D Jackson; B Bentley
Journal:  Paediatr Perinat Epidemiol       Date:  1993-04       Impact factor: 3.980

10.  Osteoporosis in cystic fibrosis.

Authors:  D T Gibbens; V Gilsanz; M I Boechat; D Dufer; M E Carlson; C I Wang
Journal:  J Pediatr       Date:  1988-08       Impact factor: 4.406

View more
  7 in total

1.  Controlled longitudinal study of bone mass accrual in children and adolescents with cystic fibrosis.

Authors:  H M Buntain; P J Schluter; S C Bell; R M Greer; J C H Wong; J Batch; P Lewindon; C E Wainwright
Journal:  Thorax       Date:  2005-12-29       Impact factor: 9.139

2.  Bone mineral content, corrected for height or bone area, measured by DXA is not reduced in children with chronic renal disease or in hypoparathyroidism.

Authors:  S Faisal Ahmed; Shiuli Russell; Rajeeb Rashid; T James Beattie; Anna V Murphy; Ian J Ramage; Heather Maxwell
Journal:  Pediatr Nephrol       Date:  2005-07-27       Impact factor: 3.714

Review 3.  Musculoskeletal and neuromuscular interventions: a physical approach to cystic fibrosis.

Authors:  Mary Massery
Journal:  J R Soc Med       Date:  2005       Impact factor: 5.344

4.  Bone mineral and body composition alterations in paediatric cystic fibrosis patients.

Authors:  Philippe Reix; Gabriel Bellon; Pierre Braillon
Journal:  Pediatr Radiol       Date:  2009-12-03

5.  Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study.

Authors:  S P Conway; B Oldroyd; A Morton; J G Truscott; D G Peckham
Journal:  Thorax       Date:  2004-08       Impact factor: 9.139

Review 6.  Pediatric DXA: clinical applications.

Authors:  Larry A Binkovitz; Paul Sparke; Maria J Henwood
Journal:  Pediatr Radiol       Date:  2007-04-13

7.  Bone and body composition analyzed by Dual-energy X-ray Absorptiometry (DXA) in clinical and nutritional evaluation of young patients with Cystic Fibrosis: a cross-sectional study.

Authors:  Vincenzina Lucidi; Carla Bizzarri; Federico Alghisi; Sergio Bella; Beatrice Russo; Graziamaria Ubertini; Marco Cappa
Journal:  BMC Pediatr       Date:  2009-09-28       Impact factor: 2.125

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.